Updated overall survival (ITT). CI confidence interval, HR hazard... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
TAGRISSO® (osimertinib) | AURA3 Study
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers | Nature Communications
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer | NEJM
JCM | Free Full-Text | Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis - Hirashima - 2019 - Cancer Science - Wiley Online Library
Supplemental Materials for Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer - Lung Cancer
Asia Pacific Biotech News
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice | SpringerLink
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. - Abstract - Europe PMC
d.planchard on Twitter: "Important result awaiting in EGFR mut pts :OS of AURA3 trial : just confirm to use osimertinib first line @myESMO #esmoasia19 https://t.co/Dwh04T0C4N" / Twitter
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
Real-World Data Of Osimertinib In Patients With Pretreated Non-Small C | CMAR
